[Skip to Navigation]
From The Medical Letter on Drugs and Therapeutics
May 7, 2019

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

JAMA. 2019;321(17):1720-1721. doi:10.1001/jama.2019.2702
×